Clostridium difficile in paediatric populations

被引:8
|
作者
Allen, Upton D. [1 ]
机构
[1] Canadian Paediat Soc, Infect Dis & Immunizat Comm, Ottawa, ON K1G 4J8, Canada
关键词
CDI; Colitis; Diarrhea; Immunocompromise; Megacolon; Metronidazole; NAP1; Vancomycin; PROTON PUMP INHIBITORS; MULTICENTER EVALUATION; FECAL BACTERIOTHERAPY; CONTROLLED-TRIAL; CYTOTOXIN ASSAY; UNITED-STATES; FUSIDIC ACID; RISK-FACTORS; DIARRHEA; INFECTION;
D O I
10.1093/pch/19.1.43
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
An increase in Clostridium difficile infection incidence has been observed among hospitalized children in the United States. The present statement, targeted at clinicians caring for infants and children in community and institutional settings, summarizes the relevant information relating to the role of C difficile in childhood diarrhea and provides recommendations for diagnosis, prevention and treatment. Significant differences between adult and paediatric risk factors and disease are discussed, along with emerging therapies. The relationship between age and disease severity in children with a newly emergent and more fluoroqinolone-resistant strain of C difficile (North American Pulse-field type-1 [NAP1]) remains unknown. The importance of antimicrobial stewardship as a preventive strategy is highlighted. This statement replaces a previous Canadian Paediatric Society position statement on C difficile published in 2000.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 50 条
  • [21] Clostridium difficile infection in general surgery patients; identification of high-risk populations
    Rodrigues, M. A.
    Brady, R. R.
    Rodrigues, J.
    Graham, C.
    Gibb, A. P.
    INTERNATIONAL JOURNAL OF SURGERY, 2010, 8 (05) : 368 - 372
  • [22] Epidemiology, diagnosis and treatment of Clostridium difficile infection
    Bassetti, Matteo
    Villa, Giovanni
    Pecori, Davide
    Arzese, Alessandra
    Wilcox, Mark
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2012, 10 (12) : 1405 - 1423
  • [23] Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic valuee
    D'Ostroph, Amanda R.
    So, Tsz-Yin
    INFECTION AND DRUG RESISTANCE, 2017, 10 : 365 - 375
  • [24] Clostridium difficile in visceral surgery
    Herzog, T.
    Deleites, C.
    Belyaev, O.
    Chromik, A. M.
    Uhl, W.
    CHIRURG, 2015, 86 (08): : 781 - 786
  • [25] Clostridium difficile associated disease
    Hassoun, Ali
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [26] Clostridium difficile infection: review
    Czepiel, Jacek
    Drozdz, Miroslaw
    Pituch, Hanna
    Kuijper, Ed J.
    Perucki, William
    Mielimonka, Aleksandra
    Goldman, Sarah
    Wultanska, Dorota
    Garlicki, Aleksander
    Biesiada, Grazyna
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (07) : 1211 - 1221
  • [27] Cadazolid for the treatment of Clostridium difficile
    Endres, Bradley T.
    Basseres, Eugenie
    Alam, M. Jahangir
    Garey, Kevin W.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (04) : 509 - 514
  • [28] Clostridium difficile in visceral surgery
    Herzog, T.
    Deleites, C.
    Belyaev, O.
    Chromik, A. M.
    Uhl, W.
    CHIRURG, 2015, 86 (08): : 781 - 786
  • [29] Clostridium difficile-associated diseases in childhood and adolescence
    Weichert, S.
    Simon, A.
    von Mueller, L.
    Adam, R.
    Schroten, H.
    MONATSSCHRIFT KINDERHEILKUNDE, 2015, 163 (05) : 427 - 436
  • [30] Therapy of Clostridium difficile infection: perspectives on a changing paradigm
    Tran, Mai-Chi N.
    Claros, Marina C.
    Goldstein, Ellie J. C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (17) : 2375 - 2386